North America Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Drug Class (Steroids, Antidepressants, Ant seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
The chemotherapy induced peripheral neuropathy market in North America is expected to grow from US$ 297.89 billion in 2021 to US$ 426.71 billion by 2028. It is estimated to grow at a CAGR of 5.3% from 2021 to 2028.
Cancer causes millions of deaths across the region each year, and although medicine is making great strides, many persistent issues need to be addressed to improve cancer treatment. Therefore, oncology research groups are focused on finding new and efficient treatments that can reduce the key side effects of traditional treatments. In April 2021, WEX Pharmaceuticals Inc., a biotechnology company engaged in developing Halneuron for chronic pain, published two clinical studies on Tetrodotoxin (TTX) as a Therapeutic Agent in a special issue of the Toxins Journal. In March 2020, Senzer Pharmaceuticals secured the Investigational New Drug (IND) application and data package for its ongoing FDA registration program for its former US strategic partner to get approval for its cannabinoid respiratory device for the treatment of the side effects induced by anti-cancer drugs. In February 2020, NoNo Inc., a privately held biotechnology company, reported a novel peptide named nerinetide, without the prior administration of alteplase. This has demonstrated important clinical improvements in patients with acute ischemic stroke in a multicenter, randomized study. Such developments and launches of new products are likely to bring new trends in the chemotherapy-induced peripheral neuropathy market in the coming years.
By offering products and services with new features and technologies, vendors in the North America chemotherapy induced peripheral neuropathy market can attract a larger base of customers and expand their footprints in emerging markets. This factor is likely to drive the market at a substantial CAGR during the forecast period.
North America Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Billion)
Get more information on this report :
North America Chemotherapy Induced Peripheral Neuropathy Market Segmentation
The North America chemotherapy induced peripheral neuropathy market is segmented on the basis of drug class, distribution channel, and country. Based on drug class, the market is segmented into steroids, anti-seizure, narcotics, and antidepressants. In 2021, the steroids segment held the largest share of the market, and anti-seizure is expected to register the highest CAGR during the forecast period. Based on distribution channel, the North America chemotherapy induced peripheral neuropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, the hospital pharmacies segment held the largest market share, and the retail pharmacies segment is expected to register the highest CAGR in the market during the forecast period. Based on country, the North America chemotherapy induced peripheral neuropathy market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest market share, and it is expected to record the fastest CAGR during the forecast period.
REGENACY PHARMACEUTICALS, INC.; Asahi Kasei Pharma Corporation; Novaremed AG; MAKScientific, LLC; WEX Pharmaceuticals Inc.; Sova Pharmaceuticals, Inc.; Kineta, Inc.; Aptinyx Inc.; Apexian Pharmaceuticals, Inc.; and WinSanTor, Inc. are among the leading companies in the North America chemotherapy induced peripheral neuropathy market.
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Chemotherapy Induced Peripheral Neuropathy Market – By Drug Class
1.3.2 North America Chemotherapy Induced Peripheral Neuropathy Market – By Distribution Channel
1.3.3 North America Chemotherapy Induced Peripheral Neuropathy Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Chemotherapy Induced Peripheral Neuropathy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. North America Chemotherapy Induced Peripheral Neuropathy Market Dynamics
5.1 Market Drivers
5.1.1 Raising Prevalence of Cancer
5.1.2 Surging Preference for Chemotherapy
5.2 Market Restraints
5.2.1 Limited Consolidated Guidelines for Chemotherapy
5.3 Future Trends
5.3.1 Burgeoning Clinical Trials for Chemotherapeutic Drugs
5.4 Impact Analysis
6. North America Chemotherapy Induced Peripheral Neuropathy Market Analysis
6.1 North America Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis
7. North America Chemotherapy Induced Peripheral Neuropathy Market – by Drug Class
7.1 Overview
7.2 Drug Class Market Revenue and Forecast Analysis (US$ Million)
7.3 Steroids
7.3.1 Overview
7.3.2 Steroids Revenue and Forecast to 2028 (US$ Million)
7.4 Antidepressants
7.4.1 Overview
7.4.2 Antidepressants Revenue and Forecast to 2028 (US$ Million)
7.5 Anti-seizure
7.5.1 Overview
7.5.2 Anti-seizure Revenue and Forecast to 2028 (US$ Million)
7.6 Narcotics
7.6.1 Overview
7.6.2 Narcotics Revenue and Forecast to 2028 (US$ Million)
8. North America Chemotherapy Induced Peripheral Neuropathy (CIPN) Market – by Distribution Channel
8.1 Overview
8.2 Distribution Channel Market Revenue and Forecast Analysis (US$ Million)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
8.4 Retail Pharmacy
8.4.1 Overview
8.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
8.5 Online Pharmacy
8.5.1 Overview
8.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
9. North America Chemotherapy Induced Peripheral Neuropathy Market – Country Analysis
9.1 Overview
9.1.1 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)
9.1.1.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.2 US: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)
9.1.1.1.3 US: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)
9.1.1.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)
9.1.1.2.3 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)
9.1.1.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.1 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.2 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)
9.1.1.3.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)
10. North America Chemotherapy Induced Peripheral Neuropathy Market– Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
10.3 Inorganic Developments
10.3.1 Overview
11. Company Profiles
11.1 REGENACY PHARMACEUTICALS, INC.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Asahi Kasei Pharma Corporation
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 MAKScientific, LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 WEX Pharmaceuticals Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sova Pharmaceuticals, Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Kineta, Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Aptinyx Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Apexian Pharmaceuticals, Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 WinSanTor, Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 SWOT Analysis
11.9.5 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. US Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 2. US Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 3. Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 4. Canada Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 5. Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 6. Mexico Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 7. Organic Developments Done By Companies
Table 8. Inorganic Developments Done By Companies
Table 9. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Chemotherapy Induced Peripheral Neuropathy Market Segmentation
Figure 2. North America Chemotherapy Induced Peripheral Neuropathy Market, By Country
Figure 3. North America Chemotherapy Induced Peripheral Neuropathy Market Overview
Figure 4. Steroids Segment Held Largest Share of Drug Class Segment in Chemotherapy Induced Peripheral Neuropathy Market
Figure 5. The US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America Chemotherapy Induced Peripheral Neuropathy Market, Industry Landscape
Figure 7. North America: PEST Analysis
Figure 8. Experts Opinion
Figure 9. Impact Analysis of Drivers and Restraints Pertaining to Chemotherapy Induced Peripheral Neuropathy Market
Figure 10. North America Chemotherapy Induced Peripheral Neuropathy Market– Revenue Forecast And Analysis – 2020- 2028
Figure 11. Drug Class Market Analysis and Forecast 2021 and 2028 (%)
Figure 12. Steroids Revenue and Forecast to 2028 (US$ Million)
Figure 13. Antidepressants Revenue and Forecast to 2028 (US$ Million)
Figure 14. Anti-seizure Revenue and Forecast to 2028 (US$ Million)
Figure 15. Narcotics Revenue and Forecast to 2028 (US$ Million)
Figure 16. Distribution Channel Market Analysis and Forecast 2021 and 2028 (%)
Figure 17. Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
Figure 18. Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
Figure 19. Online Pharmacy Market Revenue and Forecast to 2028 (US$ Million)
Figure 20. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (US$ Million)
Figure 21. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)
Figure 22. US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)
- REGENACY PHARMACEUTICALS, INC.
- Asahi Kasei Pharma Corporation
- MAKScientific, LLC
- WEX Pharmaceuticals Inc.
- Sova Pharmaceuticals, Inc.
- Kineta, Inc.
- Aptinyx Inc.
- Apexian Pharmaceuticals, Inc.
- WinSanTor, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Chemotherapy Induced Peripheral Neuropathy market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America Chemotherapy Induced Peripheral Neuropathy market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the Chemotherapy Induced Peripheral Neuropathy market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution